stockrow
Saturday 7 November 2026
Export VBIO’s income statement to Excel — free account
Valion Bio, Inc.
VBIO Healthcare Biotechnology
Valion Bio, Inc.’s revenue for fiscal 2024 (year ended December 2024) was $780,000.00, down 33.7% from fiscal 2023.
- Revenue
- +15.9%
- EPS
- +0.91%
- Free cash flow
- −189.0%
Quarter to June 2026, against a year earlier
0.51
0.01
+2.00%
Follow VBIO
Alert me
| Dec '17 | Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | Dec '24 | Dec '25 | |
|---|---|---|---|---|---|---|---|---|
Piotroski F-Score |
— | — | — | 5 | 5 | 4 | 3 | — |
P/E ratio |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Altman Z-Score |
— | — | — | 2.68 | (10.07) | (14.03) | (21.96) | — |
P/S ratio |
— | 17.80 | 17.80 | 13.12 | 3.03 | 2.28 | 3.49 | — |
Altman Z″-Score (non-manufacturers) |
— | (7.24) | (37.10) | 6.85 | (22.47) | (28.17) | (45.97) | — |
P/FCF ratio |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Beneish M-Score |
— | — | — | — | (4.22) | (1.29) | 48.80 | — |
P/Operating CF |
— | (13.42) | (13.42) | (5.97) | (2.50) | (1.51) | (2.00) | — |
P/B ratio |
— | 0.00 | 0.00 | 1.24 | 1.53 | 0.75 | 1.08 | — |
Price to Tangible BV |
— | 0.00 | 0.00 | 1.24 | 1.53 | 0.75 | 1.08 | — |
EV/Sales |
— | 18.88 | 18.88 | 3.23 | 1.31 | (0.40) | 1.24 | — |
EV/EBITDA |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.06 | 0.00 | — |
EV/Operating CF |
— | (3.98) | (3.98) | (0.72) | (0.27) | 0.05 | (0.17) | — |
EV/FCF |
— | (3.98) | (3.98) | (0.72) | (0.27) | 0.05 | (0.17) | — |
Quick Ratio |
— | 3.56 | 0.86 | 10.72 | 1.93 | 2.55 | 7.61 | 19.57 |
Current Ratio |
— | 4.55 | 1.17 | 11.72 | 2.83 | 3.32 | 9.70 | 20.13 |
Net Debt/EBITDA |
— | 0.70 | (0.14) | 3.22 | 0.32 | 0.42 | 0.49 | 0.79 |
Debt/Assets |
0.00% | 0.00% | 93.60% | 3.62% | 6.25% | 0.00% | 0.00% | 20.42% |
Debt/Equity |
— | 0.00 | (1.22) | 0.04 | 0.10 | 0.00 | 0.00 | 0.27 |
Asset Turnover |
— | 0.28 | 0.38 | 0.15 | 0.18 | 0.21 | 0.20 | 0.00 |
Operating CF/Net income |
— | 0.88 | 0.83 | 0.66 | 0.88 | 1.03 | 1.01 | 0.77 |
Capex/Depreciation |
— | (0.09) | 0.00 | 0.00 | (0.06) | (0.65) | 0.00 | (5.70) |
Interest Coverage |
— | (8.22) | (7.57) | (3.09) | 5,049.00 | 8,245.00 | 746.00 | (54.10) |
| — | (695.97%) | (610.57%) | (140.47%) | (119.47%) | (228.68%) | (184.96%) | (93.69%) | |
| — | (274.34%) | (159.78%) | (102.54%) | (96.56%) | (149.46%) | (142.01%) | (52.63%) | |
ROIC |
— | (3,794.79%) | 0.00% | (418.13%) | (1,314.84%) | (2,785.47%) | (524.86%) | (27.46%) |
Return on Tangible Assets |
— | (176.66%) | (1,509.96%) | (64.93%) | (293.49%) | (244.41%) | (238.71%) | (36.22%) |
Average Days of Receivables |
— | 11.30 | 22.07 | 26.71 | 21.23 | 54.01 | 32.29 | — |
Research and Development Expense of Revenue |
— | 235.71% | 76.63% | 69.85% | 94.02% | 140.73% | 168.33% | 0.00% |
Selling, General and Administrative Expense of Revenue |
— | 562.86% | 269.77% | 375.26% | 471.03% | 584.78% | 405.51% | 0.00% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.18 |
Share Based Compensation of Revenue |
— | 2.38% | 9.07% | 4.53% | 21.63% | 23.04% | 29.36% | 0.00% |
Graham Net Nets |
— | 0.06 | 0.06 | 0.76 | 0.55 | 1.14 | 0.87 | — |
Graham Number |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Earnings Yield |
— | (37.42%) | (37.42%) | (62.69%) | (160.37%) | (1,160.08%) | (504.97%) | — |
Free Cash Flow Yield |
— | (26.65%) | (26.65%) | (34.03%) | (160.40%) | (321.16%) | (214.38%) | — |
Revenue per Share |
— | 7,760.53 | 15,870.09 | 15,293.83 | 8,080.45 | 630.23 | 67.83 | 0.00 |
Operating CF per Share |
— | (67,812.27) | (55,859.01) | (68,280.81) | (39,168.24) | (4,561.09) | (497.83) | (151.49) |
Capex per Share |
— | (572.80) | 0.00 | 0.00 | (48.31) | (63.24) | 0.00 | (12.58) |
Free Cash Flow per Share |
— | (68,385.07) | (55,859.01) | (68,280.81) | (39,216.55) | (4,624.33) | (497.83) | (164.07) |
Cash per Share |
— | 42,701.40 | 19,265.55 | 157,865.92 | 15,445.08 | 1,819.40 | 174.09 | 273.70 |
Shareholders Equity per Share |
— | 43,810.05 | (21,719.87) | 161,479.50 | 15,941.33 | 1,918.54 | 220.43 | 523.10 |
Interest Debt per Share |
— | 0.00 | 0.03 | 0.01 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
— | 43,810.05 | (21,719.87) | 161,479.50 | 15,941.33 | 1,918.54 | 220.43 | 523.10 |
Free Cash Flow |
— | (3.70) | (3.03) | (5.61) | (8.93) | (8.63) | (5.72) | (7.58) |
Working Capital |
— | 2.32 | 0.22 | 13.07 | 3.43 | 3.25 | 2.37 | 12.36 |
Capital Expenditures |
— | (0.03) | — | — | (0.01) | (0.12) | — | (0.58) |
Net Current Asset Value |
— | 2.32 | (1.21) | 12.53 | 3.06 | 3.08 | 2.37 | 5.57 |
EV/EBIT |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.06 | 0.00 | — |
Capex to Sales |
— | 0.07 | 0.00 | 0.00 | 0.01 | 0.10 | 0.00 | 0.00 |
Price to Operating Income |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
| Other line items | ||||||||
Depreciation/Fixed assets |
— | 13.15 | 22.05 | 161.00 | 14.50 | 1.49 | 176.00 | 0.01 |
Cash ROIC |
— | (79.05%) | (232.85%) | (20.95%) | (118.84%) | (123.71%) | (126.18%) | (17.52%) |
Accounts Receivable Turnover |
— | 12.92 | 26.46 | 17.46 | 18.49 | 8.37 | 6.42 | — |
Accounts Payable Turnover |
— | 1.92 | 2.94 | 2.23 | 1.46 | 0.87 | 1.86 | 0.00 |
Inventory Turnover |
— | 1.98 | 3.03 | 3.87 | 2.39 | 1.10 | 1.45 | — |
Average Days of Payables |
— | 189.96 | 124.47 | 222.38 | 313.36 | 292.74 | 58.64 | 0.00 |
Days of Inventory on Hand |
— | 244.53 | 81.07 | 120.92 | 204.41 | 310.39 | 149.66 | — |
Average Receivables |
— | 0.03 | 0.03 | 0.07 | 0.10 | 0.14 | 0.12 | — |
Average Payables |
— | 0.37 | 0.37 | 0.58 | 1.06 | 1.02 | 0.42 | 0.19 |
Average Inventory |
— | 0.36 | 0.36 | 0.34 | 0.65 | 0.81 | 0.54 | — |
Average Assets |
— | 1.51 | 2.28 | 8.28 | 10.46 | 5.52 | 3.98 | 17.21 |
Average Common Equity |
— | 0.60 | 0.60 | 6.05 | 8.45 | 3.61 | 3.06 | 9.67 |
Columns are period end dates · fundamentals updated 26 Oct 2026